Literature DB >> 26385488

Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: A retrospective observational single center study.

Marco Skardelly1,2, Elina Brendle1, Susan Noell1,2, Felix Behling1,2, Thomas V Wuttke1,2,3, Jens Schittenhelm2,4, Sotirios Bisdas2,5, Christoph Meisner6, Sabine Rona1, Marcos Soares Tatagiba1,2, Ghazaleh Tabatabai1,2,7,8,9.   

Abstract

OBJECTIVE: Antiepileptic treatment of brain tumor patients mainly depends on the individual physician's choice rather than on well-defined predictive factors. We investigated the predictive value of defined clinical parameters to formulate a model of risk estimations for subpopulations of brain tumor patients.
METHODS: We enclosed 650 patients > 18 years of age who underwent brain tumor surgery and included a number of clinical data. Logistic regressions were performed to determine the effect sizes of seizure-related risk factors and to develop prognostic scores for the occurrence of preoperative and early postoperative seizures.
RESULTS: A total of 492 patients (334 gliomas) were eligible for logistic regression for preoperative seizures, and 338 patients for early postoperative seizures. Age ≤ 60 years (odds ratio [OR] = 1.66, p = 0.020), grades I and II glioma (OR = 4.00, p = 0.0002), total tumor/edema volume ≤ 64cm(3) (OR = 2.18, p = 0.0003), and frontal location (OR = 2.28, p = 0.034) demonstrated an increased risk for preoperative seizures. Isocitrate-dehydrogenase mutations (OR = 2.52, p = 0.026) were an independent risk factor in the glioma subgroup. Age ≥ 60 years (OR = 3.32, p = 0.041), total tumor/edema volume ≤ 64cm(3) (OR = 3.17, p = 0.034), complete resection (OR = 15.50, p = 0.0009), diencephalic location (OR = 12.2, p = 0.013), and high-grade tumors (OR = 5.67, p = 0.013) were significant risk factors for surgery-related seizures. Antiepileptics (OR = 1.20, p = 0.60) did not affect seizure occurrence. For seizure occurrence, patients could be stratified into 3 prognostic preoperative and into 2 prognostic early postoperative groups.
INTERPRETATION: Based on the developed prognostic scores, seizure prophylaxis should be considered in high-risk patients and patient stratification for prospective studies may be feasible in the future.
© 2015 American Neurological Association.

Entities:  

Mesh:

Year:  2015        PMID: 26385488     DOI: 10.1002/ana.24522

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Mutating Our Understanding of Brain Tumors and Seizures: Entrez IDH.

Authors:  Jong Woo Lee
Journal:  Epilepsy Curr       Date:  2017 Nov-Dec       Impact factor: 7.500

2.  Management of epilepsy in brain tumors.

Authors:  Marta Maschio; Umberto Aguglia; Giuliano Avanzini; Paola Banfi; Carla Buttinelli; Giuseppe Capovilla; Marina Maria Luisa Casazza; Gabriella Colicchio; Antonietta Coppola; Cinzia Costa; Filippo Dainese; Ornella Daniele; Roberto De Simone; Marica Eoli; Sara Gasparini; Anna Teresa Giallonardo; Angela La Neve; Andrea Maialetti; Oriano Mecarelli; Marta Melis; Roberto Michelucci; Francesco Paladin; Giada Pauletto; Marta Piccioli; Stefano Quadri; Federica Ranzato; Rosario Rossi; Andrea Salmaggi; Riccardo Terenzi; Paolo Tisei; Flavio Villani; Paolo Vitali; Lucina Carla Vivalda; Gaetano Zaccara; Alessia Zarabla; Ettore Beghi
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

3.  Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma.

Authors:  Steven Tobochnik; Emily Lapinskas; Jayne Vogelzang; Keith L Ligon; Jong Woo Lee
Journal:  J Neurooncol       Date:  2022-06-17       Impact factor: 4.506

4.  Risk factors for the development of epilepsy in patients with brain metastases.

Authors:  Fabian Wolpert; Anna Lareida; Robert Terziev; Bettina Grossenbacher; Marian C Neidert; Patrick Roth; Rositsa Poryazova; Lukas L Imbach; Emilie Le Rhun; Michael Weller
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

Review 5.  Stimulation-related intraoperative seizures during awake surgery: a review of available evidences.

Authors:  Elena Roca; Johan Pallud; Francesco Guerrini; Pier Paolo Panciani; Marco Fontanella; Giannantonio Spena
Journal:  Neurosurg Rev       Date:  2019-12-03       Impact factor: 3.042

6.  Image Analysis Reveals Microstructural and Volumetric Differences in Glioblastoma Patients with and without Preoperative Seizures.

Authors:  Stefanie Bette; Melanie Barz; Huong Ly Nham; Thomas Huber; Maria Berndt; Arthur Sales; Friederike Schmidt-Graf; Hanno S Meyer; Yu-Mi Ryang; Bernhard Meyer; Claus Zimmer; Jan S Kirschke; Benedikt Wiestler; Jens Gempt
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

7.  Younger age at surgery and lesser seizure frequency as prognostic factors for favorable seizure-related outcome after glioma resection in adults.

Authors:  Zhe-Ren Tan; Xiao-Yan Long; Zhi-Quan Yang; Jun Huang; Qing-Yuan Hu; Hao-Dong Yang; Guo-Liang Li
Journal:  Oncotarget       Date:  2017-06-27

8.  Early postoperative seizures (EPS) in patients undergoing brain tumour surgery.

Authors:  Tunc Faik Ersoy; Sami Ridwan; Alexander Grote; Roland Coras; Matthias Simon
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

9.  SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.

Authors:  Tobias Walbert; Rebecca A Harrison; David Schiff; Edward K Avila; Merry Chen; Padmaja Kandula; Jong Woo Lee; Emilie Le Rhun; Glen H J Stevens; Michael A Vogelbaum; Wolfgang Wick; Michael Weller; Patrick Y Wen; Elizabeth R Gerstner
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

10.  ATRX immunostaining predicts IDH and H3F3A status in gliomas.

Authors:  Azadeh Ebrahimi; Marco Skardelly; Irina Bonzheim; Ines Ott; Helmut Mühleisen; Franziska Eckert; Ghazaleh Tabatabai; Jens Schittenhelm
Journal:  Acta Neuropathol Commun       Date:  2016-06-16       Impact factor: 7.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.